In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).

We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

Time Stamps
0:00​ – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates

So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

Similar Posts

BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

Listen, Videos

Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.

In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
3. Compass Pathways (CMPS) has amazing new price targets
4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates

​…
​Timestamps:
0:00​ – Intro
1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#MMEDStock #CMPS Stock

I Just SOLD Half My MINDMED Shares And I’m Crying 😢 (MMED / MNMD)

I Just SOLD Half My MINDMED Shares And I’m Crying 😢 (MMED / MNMD)

Listen, Videos

So I just sold about HALF of my MindMed shares. But BEFORE you all FREAK OUT AND UNSUBSCRIBE, watch the rest of this episode and I can ASSURE YOU, there’s some good reasons there and none of them are about me losing faith in MMED/MNMD.
I love MindMed. My MMED holdings have more than 10Xed since the company IPOed and I will keep the rest of my MindMed holdings probably forever!

Enjoy the episode!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Website: https://thepsychedelicinvestor.com/
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindmedNews

Why the SHROOM BOOM Isn’t Just About Psychedelic Mushrooms

Why the SHROOM BOOM Isn’t Just About Psychedelic Mushrooms

Learn, Videos

How mushrooms are taking over the healthcare industry, and how investors can profit off of this. First we will talk about how they are being used as treatments for mental health conditions. And then we will talk about how regular, non psychedelic mushrooms are being used to promote healthy lifestyles, and perhaps even lengthen lifespans and increase quality of life.
The psychedelic craze has overshadowed another important facet of mushrooms and the Shroom Boom.
The health benefits and investing opportunities of non-psychedelic mushrooms.
Fungi like Lion’s Mane, Chaga and reishi have a variety of health benefits, and have recently been labelled as superfoods.
For example, Reishi mushrooms, which have been “revered in Asian societies for thousands of years”, have antibacterial, antiviral, and anti-fungal characteristics, and is high in proteins and vitamins.
While this is great news for you health, and I personally incorporate mushroom extracts into my diet, on this channel we also focuses on investing.
According to the Grand View Research Corporation, the global mushroom market, not including the psychedelic variety, is set to grow to an eye watering $50 billion annually by 2025.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

The Psychedelic Investor was compensated $1,000 by Future Money Trends for the having the interview with PlantX CEO. James (The Psychedelic Investor) does not own a position in PlantX and will not open one for at least 30 days after publication of this video.

Full Disclaimer
https://www.goldstandardir.com/plantx-life-disclaimer-85/

#ShroomBoom​​​ ​#PlantX​​​ #PsychedelicStocks

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Listen, Podcasts

Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.